Does perinatal antiretroviral therapy create an iatrogenic cancer risk?

Environmental and Molecular Mutagenesis

Volumn 48, Issue 3-4, 2007, Pages 210-214

  Wogan, Gerald N ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

AZT; Genotoxicity; HIV

Indexed keywords

ABACAVIR; CLASTOGEN; DIDANOSINE; LAMIVUDINE; NUCLEOSIDE ANALOG; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENIC ACTIVITY; CHEMICAL MUTAGENESIS; DRUG MIXTURE; DRUG TREATMENT FAILURE; GENE MUTATION; GENOTOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IATROGENIC DISEASE; NONHUMAN; ONCOGENE; PERINATAL DRUG EXPOSURE; REVIEW; TRANSPLACENTAL CARCINOGENESIS; TUMOR SUPPRESSOR GENE; VERTICAL TRANSMISSION;

ANIMALS; ANTI-HIV AGENTS; DNA DAMAGE; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MATERNAL-FETAL EXCHANGE; MUTAGENESIS; NEOPLASMS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

MUS;

EID: 34047198933     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20283     Document Type: Review

References (20)

1. Anderson LM. 2004. Introduction and overview. Perinatal carcinogenesis: Growing a node for epidemiology, risk management, and animal studies. Toxicol Appl Pharmacol 199:85-90.
2. Carter MM, Torres SM, Cook DL Jr, McCash CL, Yu M, Walker VE, Walker DM. 2007. Relative mutagenic potencies of several nucleoside analogs, alone or in drug pairs, at the HPRT and TK loci of human TK6 lymphoblastoid cells. Environ Mol Mutagen 48:239-247.
3. Cooper ER, Churarat M, Mofensen M, Hanson IC, Pitt J, Diaz C, Hayani K, Handelsman E, Smeriglio V, Hoff R, Blattner W, Women and Infants' Transmission Study Group. 2002. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 29:484-494.
4. Dobrovolsky VN, Shaddock JG, Mittelstaedt RA, Bishop ME, Lewis SM, Lee FW, Aidoo A, Leakey JEA, Dunnick JK, Heflich RH. 2007. Frequency of hprt mutant lympohocytes and micronucleated erythrocytes in p53-haplodeficient mice treated perinatally with AZT, AZT in combination with 3TC. Environ Mol Mutagen 48:270-282.
5. Escobar PA, Olivero OA, Wade NA, Abrams EJ, Nesel CJ, Ness RB, Day RD, Day BW, Meng Q, O'Neill JP, Walker DM, Poirier MC, Walker VE, Bigbee WL, for the Study Team. 2007. Genotoxicity assessed by the Comet and GPA assays following in vitro exposure of human lymphoblastoid cells (H9) or perinatal exposure of mother-child pairs to AZT or AZT-3TC. Environ Mol Mutagen 48:330-343.
6. European Collaborative Study. 2003. Exposure to antiretroviral therapy in utero or early life: The health of uninfected children born to HIV-infected mothers. J Acquir Immune Defic Syndr 32:380-387.
7. Fu PP, von Tungeln LS, Hammons GJ, McMahon G, Wogan G, Flammang TJ, Kadlubar FF. 2000. Metabolic activation capacity of neontatal mice in relation to the neonatal mouse tumorigenicity assay. Drug Metab Rev 32:241-266.
8. Hong H-H, Dunnick J, Herbert R, Devereux TR, Kim Y, Sills RC. 2007. Genetic alterations in K-ras and p53 cancer genes in lung neoplasms from Swiss (CD-1) male mice exposed transplacentally to AZT. Environ Mol Mutagen 48:299-306.
9. International Agency for Research on Cancer. 2000. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 76: Some Antiviral and Antineoplastic Drugs, and other Pharmaceutical Agents. Lyon:IARC. pp 35-127.
10. Meng Q, Olivero OA, Fasco MJ, Bellisario R, Kaminsky L, Pass KA, Wade NA, Abrams EJ, Nesel CJ, Ness RB, Bigbee WL, O'Neill JP, Walker DM, Poirier MC, Walker VE, for the Study Team. 2007. Plasma and cellular markers of AZT metabolism as indicators of DNA damage in cord blood mononuclear cells from infants receiving prepartum NRTIs. Environ Mol Mutagen 48:307-321.
11. Olivero OA. 2007. Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors. Environ Mol Mutagen 48:215-223.
12. Olivero OA, Anderson LM, Diwan BA, Haines DC, Harbaugh SW, Moskal TJ, Jones AB, Rice JM, Riggs CW, Logsdon D, Yuspa SH, Poirier MC. 1997. Transplacental effects of 3′-azido-2′3′-dideoxythymidine (AZT) in mice and genotoxicity in monkeys. J Natl Cancer Inst 89:1602-1608.
13. Rice JM. 1981. Prenatal susceptibility to carcinogenesis by xenobiotic substances including vinyl chloride. Environ Health Perspect 41:179-188.
14. Torres SM, Walker DM, Carter MM, Cook DL Jr, McCash CL, Cordova EM, Olivero OA, Poirier MC, Walker VE. 2007. Mutagenicity of zidovudine, lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD-1 mice to single agents or drug combinations. Environ Mol Mutagen 48:224-238.
15. Vesselinovitch SD. 1990. Perinatal mouse liver carcinogenesis as a sensitive carcinogenesis model and the role of sex hormonal environment in tumor development. Prog Clin Biol Res 331:53-68.
16. Vesselinovitch SD, Mihailovich N, Rao KV, Itze L. 1971. Perinatal carcinogenesis by urethan. Cancer Res 31:2143-2147.
17. Von Tungeln LS, Williams LD, Doerge DR, Shaddock JG, McGarrity LJ, Morris SM, Mittelstaedt RA, Heflich RH, Beland FA. 2007. Transplacental drug transfer and frequency of tk and hprt lymphocyte mutants and peripheral blood micronuclei in mice treated transplacentally with zidovudine and lamivudine. Environ Mol Mutagen 48:258-269.
18. Walker DM, Malarkey DE, Seilkop SK, Ruecker FA, Funk KA, Wolfe MJ, Treanor CP, Foley JF, Dunnick JK, Hardisty JF, Walker VE. 2007. Transplacental carcinogenicity of 3′-azido-3′-deoxythymidine in B6C3F, mice and F344 rats. Environ Mol Mutagen 48:283-298.
19. Wang J, Chen T, Honma M, Chen L, Moore MM. 2007. 3-Azido-3-deoxythymidine (AZT) induces deletions in L5178Y mouse lymphoma cells. Environ Mol Mutagen (Epub ahead of print).
20. Witt KL, Cunningham CK, Patterson KB, Kissling GE, Dertinger SD, Livingston E, Bishop JB. 2007. Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV. Environ Mol Mutagen 48:322-329.